#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Conjunctivitis allergic Partial lipodystrophy Uterine leiomyosarcoma Fibrosarcoma metastatic Glioma Andersen-Tawil syndrome Peripheral primitive neuroectodermal tumour of soft tissue Necrotising myositis Peritoneal mesothelioma malignant Crigler-Najjar syndrome Small cell lung cancer recurrent Anti-glomerular basement membrane disease Extra-osseous Ewing's sarcoma recurrent Meningococcal immunisation Antithrombin III deficiency More trials…

    Learn about Rare Diseases

    Carcinoid syndrome – Trials in Disease Systemic mastocytosis – Trials in Disease Primary biliary cholangitis Antisynthetase syndrome – Basic Information Angelman’s syndrome Rett syndrome – Trials in Disease Familial haemophagocytic lymphohistiocytosis – Treatment Small intestine leiomyosarcoma – Trials in Disease Atypical haemolytic uraemic syndrome – Basic Information Rett syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Rucaparib Ampicillin Sodium Galunisertib Benzylpenicillin Sodium Labetalol Hydrochloride Exagamglogene Autotemcel Messenger Rna Encoding Cas9 Cefotaxime Sodium GSK5460025A [14C] DC-806 Procarbazine Hydrochloride HUMAN FIBROBLASTS Cetirizine Dapagliflozin Propanediol Onasemnogene Abeparvovec Vb10.16 Levocetirizine Dihydrochloride Lisdexamfetamine Dimesylate Bp1.7881A ABBV-CLS-628 More therapies…

    Learn about Your Condition

    Cervix carcinoma stage II Hypertrophic cardiomyopathy Myelofibrosis Primary myelofibrosis Premature baby Glioblastoma Ataxia telangiectasia Frostbite Pneumothorax Urethral stenosis Femur fracture Ophthalmoplegia Rhabdoid tumour of the kidney Diabetic nephropathy Synovial sarcoma recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Malignant melanoma

  • Study of LTX-315 and Pembrolizumab for Patients with Advanced Melanoma Resistant to PD-1/PD-L1 Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Chlorphenamine
    • Cimetidine
    • Ltx-315
    France Norway Spain

  • Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Nivolumab
    Austria Belgium Czechia Denmark Finland France +9

  • Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Stage II-IV Melanoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Vibostolimab
    • Pembrolizumab
    Austria Belgium France Germany Ireland Italy +3

  • Study of IO102-IO103 and Pembrolizumab for Patients with Resectable Melanoma and Head and Neck Squamous Cell Carcinoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Io103 Acetate
    • Pembrolizumab
    Denmark France Germany Spain

  • Study of 89Zirconium-labeled ipilimumab distribution in patients with metastatic melanoma receiving ipilimumab/nivolumab combination therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Skin cancer
    Investigated Drugs:
    • Ipilimumab
    The Netherlands

  • Study Comparing High Dose Interferon, Ipilimumab, and Pembrolizumab for Patients with High Risk Resected Melanoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Pembrolizumab
    Ireland
Previous Page
1 … 11 12 13 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!